BOSTON, Feb. 14, 2019 /PRNewswire/ -- Lua Technologies, a subsidiary of Life Biosciences Inc, has been ranked the highest scoring post-acute secure messaging solution in the 2018 Secure Communication Decision Insights Report from KLAS Research. Lua received exceptional ratings in overall product quality, value and secure messaging performance, scoring 94 out of 100.
The rating validates Lua's mission to improve patient outcomes by facilitating secure communication between providers and patients. Lua accomplishes this through seamless communications across a web portal and native mobile applications that enhance mobile workflows in healthcare organizations.
"We are thrilled by the KLAS Research assessment of our performance as the top performing post-acute secure messaging solution," said Michael DeFranco, chief executive officer of Lua. "Lua had an extremely high overall satisfaction score and our customer satisfaction ranking is in the top quartile."
"Secure communication is a rapidly evolving market, with high variability in terms of both customer needs and vendor offerings," according to KLAS report. "This combines performance feedback from current customers with purchasing insights from 100 acute care, ambulatory, and post– acute care organizations—and examines which vendors are most often considered, what factors most influence their decisions, and how current customers rate vendor performance."
KLAS methodology includes both quantitative and qualitative evaluation of software products and services. Lua has an internally documented customer retention at 95 percent and is credited with remarkable ease of use, simple pricing and outstanding support.
As cited in the report by an owner of a home health agency, "We chose Lua because the pricing model was a lot simpler than others we had looked at. When we were doing a trial of the product, the customer service people were very responsive and available anytime that we needed them. Even after the implementation, the customer support is still excellent, and the product does what we need it to do. It is solid."
– Life Biosciences Overview –
Life Biosciences was co-founded by world renowned scientists and Tristan Edwards, who developed its innovative structure as Chapter Two in his life, after a highly successful career as a global institutional investor, working across all asset classes. Life Biosciences is the first and largest company focused on addressing health decline due to aging as a systemic breakdown of the body, rather than a series of isolated events and conditions.
There are six Daughter companies working independently and together within the Life Biosciences research environment. The company also recently announced a significant investment in Prana, a publicly traded Australian biotech company, and the acquisition of Lua, its HIPAA-compliant medical technology subsidiary. Life Biosciences provides Daughter companies with the resources required to maximize human potential, including Lua's data and communications platform, experienced management, drug development experience, and a 24,000 square foot, state-of-the-art vivarium, robotics and drug screening facility in Cambridge, Mass, augmented by laboratories and offices on four continents.
Co-founded in 2017 by world-renowned scientists and Tristan Edwards, Life Biosciences is addressing the eight pathways of age-related decline (ARD) as a systemic breakdown of the body, not a series of isolated symptoms and conditions. It has established Daughter companies around the world to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with the full resources of Life Lua's data and communications platform; LifeLab, its 24,000- square-foot, state-of-the-art research facility that includes a vivarium, robotics, and drug screening capabilities. Life Biosciences seeks to increase healthspans for everyone, including companion animals.
For more information on Life Biosciences, please visit www.lifebiosciences.com.
SOURCE Life Biosciences